77 related articles for article (PubMed ID: 21530213)
1. Premature discontinuation during the UPLIFT study.
Decramer M; Molenberghs G; Liu D; Celli B; Kesten S; Lystig T; Tashkin DP;
Respir Med; 2011 Oct; 105(10):1523-30. PubMed ID: 21530213
[TBL] [Abstract][Full Text] [Related]
2. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).
Morice AH; Celli B; Kesten S; Lystig T; Tashkin D; Decramer M
Respir Med; 2010 Nov; 104(11):1659-67. PubMed ID: 20724131
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial.
Tashkin DP; Celli BR; Decramer M; Lystig T; Liu D; Kesten S
COPD; 2012 Jun; 9(3):289-96. PubMed ID: 22432932
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial.
Fukuchi Y; Fernandez L; Kuo HP; Mahayiddin A; Celli B; Decramer M; Kesten S; Liu D; Tashkin D
Respirology; 2011 Jul; 16(5):825-35. PubMed ID: 21539680
[TBL] [Abstract][Full Text] [Related]
5. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial.
Troosters T; Celli B; Lystig T; Kesten S; Mehra S; Tashkin DP; Decramer M;
Eur Respir J; 2010 Jul; 36(1):65-73. PubMed ID: 20185426
[TBL] [Abstract][Full Text] [Related]
6. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
Tashkin DP; Celli B; Senn S; Burkhart D; Kesten S; Menjoge S; Decramer M;
N Engl J Med; 2008 Oct; 359(15):1543-54. PubMed ID: 18836213
[TBL] [Abstract][Full Text] [Related]
7. Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.
Tashkin DP
Expert Rev Respir Med; 2010 Jun; 4(3):279-89. PubMed ID: 20524910
[TBL] [Abstract][Full Text] [Related]
8. Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease.
Covelli H; Bhattacharya S; Cassino C; Conoscenti C; Kesten S
Pharmacotherapy; 2005 Dec; 25(12):1708-18. PubMed ID: 16305289
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities].
Beeh KM; Beier J; Buhl R; Stark-Lorenzen P; Gerken F; Metzdorf N;
Pneumologie; 2006 Jun; 60(6):341-6. PubMed ID: 16761228
[TBL] [Abstract][Full Text] [Related]
10. Premature discontinuation of patients: a potential bias in COPD clinical trials.
Kesten S; Plautz M; Piquette CA; Habib MP; Niewoehner DE
Eur Respir J; 2007 Nov; 30(5):898-906. PubMed ID: 17690120
[TBL] [Abstract][Full Text] [Related]
11. Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT®).
Janssens W; Liu Y; Liu D; Kesten S; Tashkin DP; Celli BR; Decramer M
Respir Med; 2013 Sep; 107(9):1409-16. PubMed ID: 23714653
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tiotropium in the prevention of exacerbations of COPD.
Anzueto A; Miravitlles M
Ther Adv Respir Dis; 2009 Jun; 3(3):103-11. PubMed ID: 19617284
[TBL] [Abstract][Full Text] [Related]
13. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease.
Ágh T; Inotai A; Mészáros Á
Respiration; 2011; 82(4):328-34. PubMed ID: 21454953
[TBL] [Abstract][Full Text] [Related]
15. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease.
Celli B; Decramer M; Kesten S; Liu D; Mehra S; Tashkin DP;
Am J Respir Crit Care Med; 2009 Nov; 180(10):948-55. PubMed ID: 19729663
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a randomized, double-blind, double-dummy, efficacy and safety study in patients with chronic obstructive pulmonary disease].
Zheng JP; Kang J; Cai BQ; Zhou X; Cao ZL; Bai CX; Zhong NS
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jun; 29(6):363-7. PubMed ID: 17045014
[TBL] [Abstract][Full Text] [Related]
17. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
Tashkin DP
Am J Med; 2006 Oct; 119(10 Suppl 1):63-72. PubMed ID: 16996901
[TBL] [Abstract][Full Text] [Related]
18. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
Sobieraj DM; White CM; Coleman CI
Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
[TBL] [Abstract][Full Text] [Related]
19. [The UPLIFT study: future perspectives].
Rodríguez González-Moro JM; Lucero S; de Lucas Ramos P
Arch Bronconeumol; 2008; 44 Suppl 2():39-48. PubMed ID: 19087842
[TBL] [Abstract][Full Text] [Related]
20. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
